AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass.–(BUSINESS WIRE)–Feb. 21, 2013–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William
Heiden, AMAG’s chief executive officer, will participate in the RBC
Capital Markets Global Healthcare Conference on Tuesday, February 26,
2013 at 9:30 am ET in New York and the Cowen and Company 33^rd
Annual Healthcare Conference on Monday, March 4, 2013 at 2:50 pm ET in
Boston. The presentations will include a company overview and business
update, followed by a question and answer session with investors.

A live webcast of the presentations will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following the conferences, the webcasts will be archived on the AMAG
Pharmaceuticals, Inc. website until April 4, 2013.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in the United States. Along with driving organic
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303